VIDEO: Treatment for older Hodgkin lymphoma patients is ‘an area of unmet need’
Brentuximab vedotin alone may not be a good option for older patients with Hodgkin lymphoma; however, brentuximab seems a reasonable choice when used in combination with other therapies, like dacarbazine.
The data were presented at the ASH Annual Meeting and Exposition.
“What I took away from this was single agent brentuximab is not a good option in older patients. Their response rates were good, but the durability was not,” Ann S. LaCasce, MD, MSc, of Dana-Farber Cancer Institute, said in a video interview. “This is an unmet area of need – our elderly patients with Hodgkin lymphoma.”
Collapse
Yasenchak CA, et al. Abstract 471. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Read more about